COVID-19

[Nature Microbiology] Researchers compared SARS-CoV-2-specific antibody and T cell responses between older adults and a younger control group after receiving two doses of BNT162b2.

[Frontiers in Immunology] According to large-scale single-cell analysis, recovered patients, who had severe symptoms, still exhibited peripheral immune disorders one-two months after symptom onset.

[Journal of Cachexia Sarcopenia and Muscle] Researchers discuss cellular and molecular pathways that are affected and consider these in regard to skeletal muscle involvement in other conditions, such as acute respiratory distress syndrome, critical illness myopathy, and post-viral fatigue syndrome.

[Nature Metabolism] The authors connected the circulating protein GP73 with enhanced hepatic gluconeogenesis during SARS-CoV-2 infection.

[First Wave BioPharma, Inc.] First Wave BioPharma, Inc. announced that it has completed enrollment for Part II of the RESERVOIR Phase II trial evaluating FW-COV as an outpatient treatment for COVID-19-related gastrointestinal infections.

[Drug Discovery Today] Investigators summarize available models as well as novel drug screening approaches, from simple to more advanced platforms.